fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Page Views : 67921
Disclaimer

company profile

 

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.

Sector
:
Healthcare
Industry
:
Biotechnology
Exchange
:
Nasdaq
Ticker
:
INMB

vista's key points

  • An exciting clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer.
  • INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer.
  • INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse.
  • By controlling residual disease, INmune believes that patients may live longer.
  • Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.